Anders Bach at University of Copenhagen
The Bach lab applies fragment-based drug discovery (FBDD) on disease-relevant protein-protein interactions in order to evaluate the druggability of selected targets and identify novel chemical probes and therapeutic principles
The aim of this project is to develop new small-molecule inhibitors and degraders of Cullin 3 (Cul3) adaptor proteins by using fragment-based drug discovery (FBDD) and proteolysis targeting chimeras (PROTACs) strategies. A particular focus will be on kelch domain-containing adaptor proteins.
Anders Bach
Department of Drug Design and Pharmacology
University of Copenhagen
